NTLA

#2071
Intellia Therapeutics, Inc
14.8600 USD
+4.21%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
14.7400
14.8800
Intervallo Annuale
7.9500
17.0900
Variazione giornaliera
+4.21%
Variazione Mensile
+13.26%
Variazione di 6 mesi
+8.31%
Variazione Annuale
+8.31%
Chiusura Precedente
14.2600
Apertura
14.7650
Bid
Ask
Minimo
14.7400
High
14.8800
Volume
62
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
  • Market Capitalization 1.7555 B
  • Employee 377
  • Founded 2014
  • CEO John Leonard
  • Website www.intelliatx.com
  • Headquarter Delaware, United States
  • FIGI BBG007KC7PB0
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-2.36
Rapporto prezzo/fatturato
14.4

Intellia Therapeutics Inc

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies.

Notizie